TriangleNCT00004881 · CITED IN SOURCE DOCUMENTS
Vaccine Therapy in Treating Patients With Advanced Cancer
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE1
- Status at capture
- COMPLETED
- Registry last update
- 2013-06-26
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
No posted result sections were captured. Registered plans do not establish that a treatment works.
Who could take part
- eligibility Criteria
- DISEASE CHARACTERISTICS: Histologically confirmed cancer not amenable to cure by any standard modality and not suitable for accepted palliative care with chemotherapy, immunotherapy, or hormonal therapy Histologically confirmed MUC1 antigen expression No uncontrolled or symptomatic CNS metastases PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 3 months Hematopoietic: Hemoglobin at least 9.0 g/dL WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) Transaminase no greater than 3 times ULN (unless attributable to metastatic disease) Renal: Creatinine no greater than 2 times ULN Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study HIV negative No active systemic infections No other serious concurrent systemic medical disorders that would preclude study compliance No history of, or immediate household contact with, eczema, exfoliative skin disorders, pregnant women, children under 3 years of age, or other immunocompromise offering an increased risk for disseminated vaccinia infection PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy (6 weeks for nitrosamines and mitomycin) No concurrent chemotherapy Endocrine therapy: See Disease Characteristics No concurrent systemic corticosteroid therapy No concurrent hormonal therapy Radiotherapy: See Disease Characteristics At least 3 weeks since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics Other: No concurrent immunosuppressive drugs No other concurrent experimental protocol No other concurrent antitumor therapy
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- interventions
- name
- MVA-MUC1-IL2 vaccine
- type
- BIOLOGICAL
Study design
- primary Purpose
- TREATMENT
Enrollment
Source nullRegistered outcome plans (not posted results)
Full study description
- brief Summary
- RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have advanced cancer.
- detailed Description
- OBJECTIVES: I. Determine the safety, tolerance, and maximum tolerated dose of TG4010 in patients with MUC1 positive advanced cancer. II. Determine the biological and immunological effects of this regimen in this patient population. OUTLINE: This is a dose escalation study. Patients receive TG4010 IM weekly for 4 weeks, every other week for 8 weeks, and then every 4 weeks. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of TG4010 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience treatment related grade 3 toxicity. If any patient experiences grade 4 toxicity, the prior dose level is considered the MTD. PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 4 months.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-048ec6141165db1296cc
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- 6e125601-ebbb-4fe6-9d9e-80d093b12532
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 3a6993593c4d2a8d4b5824b962538deb07573885c27686717e041a11faf432f6
- payload
- application numbers
- NDA210661
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-048ec6141165db1296cc
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- R) a (95% CI) 0.62 (0.49-0.79) p-value p<0.0001 Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15257
- exact text
- NCT00004881
- start
- 15246
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/41/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 6e125601-ebbb-4fe6-9d9e-80d093b12532
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c1815b42252f266daaa6ea7cd4300975a080640af963f58025c7b9cdbdd2075f
- spl effective time
- 20251008
- spl set id
- 9582c46c-d8b0-44b7-a2ee-9c86f5e9b7b1
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-05296ef802e918e269ed
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- 0c1baa15-83bb-45a0-a3ab-855a4fee9129
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- payload sha256
- a3b77a4e36a0ba208e203298506977527cdd250f40601a1460b8d2045af85596
- payload
- application numbers
- NDA210661
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-05296ef802e918e269ed
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- -Meier Curves for Overall Survival in PARAMOUNT Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 10749
- exact text
- NCT00004881
- start
- 10738
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00000.json
- source file sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source json pointer
- /results/35/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 0c1baa15-83bb-45a0-a3ab-855a4fee9129
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 3795d0040e7ac5a79c69b3e5faa265627002f44394b0c17baa15e8f36a5f9b35
- spl effective time
- 20250205
- spl set id
- adc9ce4c-926a-4ee8-bd0d-d06fc89c17fc
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-14c8623af408ab743ccd
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- b0e3847a-fdcf-405c-823c-180fa8dad9c2
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 1cad5ec9b3cd9d44f6cbb5e90a8aa243b40ebfb2ad43247b9317b179b243975f
- payload
- application numbers
- NDA215179
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-14c8623af408ab743ccd
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- -Meier Curves for Overall Survival in PARAMOUNT Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15675
- exact text
- NCT00004881
- start
- 15664
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/6/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b0e3847a-fdcf-405c-823c-180fa8dad9c2
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c6b1ed4114fefd1c7f9a6371e475849253e8c11cc50aceaeb1a969a2604b8bb9
- spl effective time
- 20241128
- spl set id
- fe432994-e61b-4a87-8c98-cc20b847d0fe
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-271931b593ac364f1194
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- 764ab64b-c642-4314-83a9-efee79fe83a3
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- payload sha256
- 91ee74f61f9e9291ef0036fb8b6670d33614e53e759b774c7d1e5ea8b8cba99e
- payload
- application numbers
- NDA214657
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-271931b593ac364f1194
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- -Meier Curves for Overall Survival in PARAMOUNT Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15437
- exact text
- NCT00004881
- start
- 15426
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00400.json
- source file sha256
- a4bef6778baed183e5bcf581938b0b23d3576dfd9eb6150f2904934a750c5fef
- source json pointer
- /results/60/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 764ab64b-c642-4314-83a9-efee79fe83a3
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- f14b6d5c8f017e0503c823927e08bef89aeae42994f80f7a2dfaadbc09020d18
- spl effective time
- 20251216
- spl set id
- 7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-7d7fd90b3547797cef0d
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- 3af0bc84-13d6-46aa-a4c0-c62410b73bc6
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- bdfbbbf591af2250228bff078f4e4fc9400d16046b90da27a75d18b25eefb50f
- payload
- application numbers
- NDA021462
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-7d7fd90b3547797cef0d
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- r Curves for Overall Survival in PARAMOUNT Figure 8 Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of ALIMTA was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15595
- exact text
- NCT00004881
- start
- 15584
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/21/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 3af0bc84-13d6-46aa-a4c0-c62410b73bc6
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- c363caf02e37fe1fcb2cfbfab2db667a44fdc5d833da1aa84c45ac81f6d9476f
- spl effective time
- 20230519
- spl set id
- f5a860f3-37ec-429c-ae04-9c88d7c55c08
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-880c912547fd04b67d2c
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- b6a00be1-95d1-4b91-93bf-4430a57eeff6
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- 1c23ebf7ebbc6fe12d92cd75848233ea2efc6d1a2541dffd40e7574bb717eea2
- payload
- application numbers
- NDA215179
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-880c912547fd04b67d2c
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- -Meier Curves for Overall Survival in PARAMOUNT Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15710
- exact text
- NCT00004881
- start
- 15699
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/19/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- b6a00be1-95d1-4b91-93bf-4430a57eeff6
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 3e0c2b31c3caff21c791ca789dbbe8d786d7c6e66e0c8ecae4db8285b6897301
- spl effective time
- 20250708
- spl set id
- 0f006b06-ab85-423d-ba0c-dfc3fc25844e
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b0660ec2aa37396018fb
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- efadeccf-c754-46aa-999e-4da07a4cd2ce
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- d05eaa573e0fb8d4171e62920115c7bb87829f7df73c6f3cb5e82368978fc7d1
- payload
- application numbers
- NDA209472
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b0660ec2aa37396018fb
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- -Meier Curves for Overall Survival in PARAMOUNT Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15974
- exact text
- NCT00004881
- start
- 15963
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/98/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- efadeccf-c754-46aa-999e-4da07a4cd2ce
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fabb7322fa01234eab10e933fa6a8ff46ccdac2d8c21ba522dd36a9932c59267
- spl effective time
- 20260220
- spl set id
- 2308f4e8-21c8-49c1-a5b8-deb8610bac6a
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-b39c44f6b084b6b576fd
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- 21155bd2-118e-4ce6-adb8-dddc69ae34c7
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- payload sha256
- 9177575dd1ff6f7869c2cbd5faacf84569e426678e41956f955a4b876372331f
- payload
- application numbers
- NDA208419
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-b39c44f6b084b6b576fd
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- -Meier Curves for Overall Survival in PARAMOUNT Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15923
- exact text
- NCT00004881
- start
- 15912
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00100.json
- source file sha256
- fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058
- source json pointer
- /results/16/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 21155bd2-118e-4ce6-adb8-dddc69ae34c7
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fff29cb5bde26b5953edee240ba643fc2fd422811dcfe7428495d3d09c04da80
- spl effective time
- 20221201
- spl set id
- 8b660f68-b770-4e0a-b2f9-25e663deecc3
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-bac31e2624b6a3bd0ab6
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- 54cf7e63-ef81-4ced-b833-a73ad8980230
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- f83ebd8681d59f7b3dfd5f827a148d89c3687e637c3cab17ae272e2f0d131b16
- payload
- application numbers
- NDA214218
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-bac31e2624b6a3bd0ab6
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- rves for Overall Survival in PARAMOUNT Figure 7 Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 10759
- exact text
- NCT00004881
- start
- 10748
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/54/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 54cf7e63-ef81-4ced-b833-a73ad8980230
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 20bda6357808aaafe1bcd8882382f9a130b4d009acdccbca54c39920e0a30764
- spl effective time
- 20251008
- spl set id
- 3ae68628-7ab0-4491-b3ae-6a8330b719c8
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-bd78bd0582ec72383e68
- requested nct id
- NCT00004881
- primary nct id
- NCT00004881
- source kind
- fda_spl_label
- source record id
- 49baf2a0-c1bf-49a8-a2f9-176cae0b7410
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- payload sha256
- 0fdfeb3dcd349c448abbe2fc9046a0d7cc7bd1dfde7c0ffa5663b67515701ca6
- payload
- application numbers
- NDA209472
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-bd78bd0582ec72383e68
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT00004881
- occurrences
- context exact
- -Meier Curves for Overall Survival in PARAMOUNT Treatment of Recurrent Disease After Prior Chemotherapy The efficacy of pemetrexed was evaluated in Study JMEI (NCT00004881), a multicenter, randomized (1:1), open-label study conducted in patients with Stage III or IV NSCLC that had recurred or progressed following one prior chemot
- end
- 15974
- exact text
- NCT00004881
- start
- 15963
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00200.json
- source file sha256
- d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571
- source json pointer
- /results/91/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 49baf2a0-c1bf-49a8-a2f9-176cae0b7410
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- fabb7322fa01234eab10e933fa6a8ff46ccdac2d8c21ba522dd36a9932c59267
- spl effective time
- 20260618
- spl set id
- caef07ce-066b-4c48-98dc-974b05ebbbe0
Preserved source evidence · Not medical advice